Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Aeovian Pharmaceuticals","sponsor":"Hevolution","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aeovian Pharmaceuticals Doses First Participants in Phase 1 Clinical Trial, Strengthens Leadership Team and Raises Additional $50 Million Financing","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by Aeovian Pharmaceuticals

    Menu

    Aeovian Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Aeovian Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Aeovian Pharmaceuticals Doses First Participants in Phase 1 Clinical Trial, Strengthens Leadership Team and Raises Additional $50 Million Financing

              Details:

              The net proceeds will support the development of AV078, a first-in-class CNS penetrant selective mTORC1 inhibitor and prepare for the start of a subsequent Phase 2 clinical trial in adult and pediatric patients with TSC refractory epilepsy.

              Lead Product(s): AV078

              Therapeutic Area: Rare Diseases and Disorders Product Name: AV078

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Hevolution

              Deal Size: $50.0 million Upfront Cash: Undisclosed

              Deal Type: Financing March 28, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY